Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy

Item
http://www.wikidata.org/entity/Q35673260
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.My treatment approach to patients with diffuse large B-cell lymphoma.Management Strategies for Elderly Patients with Diffuse Large B-Cell LymphomaSignificant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DTreatment of the elderly patient with diffuse large B cell lymphoma.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.Nanomedicine strategies for hematological malignancies: what is next?Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.Hodgkin's Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge.Guidelines for the management of diffuse large B-cell lymphoma.
P2860

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy

Item
http://www.wikidata.org/entity/Q35673260
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Biweekly rituximab, cyclophosp ...... ife threat' impact cardiopathy
@ast
Biweekly rituximab, cyclophosp ...... ife threat' impact cardiopathy
@en
type
label
Biweekly rituximab, cyclophosp ...... ife threat' impact cardiopathy
@ast
Biweekly rituximab, cyclophosp ...... ife threat' impact cardiopathy
@en
prefLabel
Biweekly rituximab, cyclophosp ...... ife threat' impact cardiopathy
@ast
Biweekly rituximab, cyclophosp ...... ife threat' impact cardiopathy
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Biweekly rituximab, cyclophosp ...... ife threat' impact cardiopathy
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2141.2011.08786.X
P407
P433
P478
P50
P577
P5875
P698
P932